Mikhail Chernov Mikhail Chernov, PhD

Mikhail Chernov

PhD

About Mikhail Chernov

Biography:

Dr. Chernov joined the staff of Roswell Park Comprehensive Cancer Center (Roswell Park) in July of 2007, as a Director of Small Molecule Screening Core Facility in the Department of Cell Stress biology.

Dr. Chernov earned an MS degree in Biochemistry and Physiology from Moscow State University (Moscow Russia) and his Ph.D. in Biochemistry in 1987 from the Cancer Research Center (Moscow Russia).

Dr. Chernov has authored or co-authored more than 30 journal publications, and abstracts.

Positions

Roswell Park Comprehensive Cancer Center
  • Director, Small Molecule Screening Core Facility
  • Assistant Member (Clinical Research)
  • Department of Cell Stress Biology

Background

Education and Training:

  • PhD - Biochemistry, Cancer Research Center, Moscow, Russia
  • MS - Biochemistry and Physiology, Moscow State University, Moscow, Russia

Research

Research Overview:

Dr. Chernov's research interest focuses on the study of regulation and function of p53 tumor suppressor and development and utilization of cell based readout systems for drug discovery.

Regulation of p53 tumor suppressor, modulation of p53 activity by small molecules

Development and utilization of cell based assays for high throughput chemical screenings


Publications

  • Yang X, Shen H, Buckley B, Chen Y, Yang N, Mussell AL, Chernov M, Kobzik L, Frangou C, Han SX, Zhang J. NTRK1 is a positive regulator of YAP oncogenic function. Oncogene. 2019 Apr;38(15):2778-2787
  • Bailey DC, Buckley BP, Chernov MV, Gulick AM. Development of a High-Throughput Biochemical Assay to Screen for Inhibitors of Aerobactin Synthetase IucA. SLAS Discov. 2018 Dec;23(10):1070-1082.
  • Wu W, Xu C, Ling X, Fan C, Buckley BP, Chernov MV, Ellis L, Li F, Muñoz IG, Wang X. Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells. Cell Death Dis. 2015 Dec 31;6:e2035.
  • Zhang F, Patel DM, Colavita K, Rodionova I, Buckley B, Scott DA, Kumar A, Shabalina SA, Saha S, Chernov M, Osterman AL, Kashina A. Arginylation regulates purine nucleotide biosynthesis by enhancing the activity of phosphoribosyl pyrophosphate synthase. Nat Commun. 2015 Jul 15;6:7517.
  • Saha S, Wang J, Buckley B, Wang Q, Lilly B, Chernov M, Kashina A. Small molecule inhibitors of arginyltransferase regulate arginylation-dependent protein degradation, cell motility, and angiogenesis. Biochem Pharmacol. 2012 Apr 1;83(7):866-73
  • Hu Y, Spengler ML, Kuropatwinski KK, Comas-Soberats M, Jackson M, Chernov MV, Gleiberman AS, Fedtsova N, Rustum YM, Gudkov AV, Antoch MP. Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein, BMAL1. Oncotarget. 2011 Dec;2(12):1279-90.
  • Luo W, Yu WD, Ma Y, Chernov M, Trump DL, Johnson CS. Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells. Cancer Res. 2013 Apr 1;73(7):2289-97.
  • Antoch MP, Chernov MV. Pharmacological modulators of the circadian clock as potential therapeutic drugs. Mutat Res. 2009 Nov-Dec;680(1-2):109-15. Review.

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment